Botulinum Toxin Applications in Hemiplegic Patients

Istanbul Physical Medicine Rehabilitation Training and Research Hospital34 enrolled

Overview

This retrospective study will be conducted by reviewing the medical records of hemiplegic patients who received botulinum toxin treatment between 2017 and 2020 at the Physical Medicine and Rehabilitation outpatient clinic of Istanbul Physical Medicine and Rehabilitation Training and Research Hospital. A total of 35 hemiplegic patients who underwent botulinum toxin injection and had at least two follow-up records (with a 6-month interval) will be included. Sociodemographic and clinical data, stroke-related characteristics, botulinum toxin dosage, injected muscle groups, medications, and comorbidities will be recorded. Functional assessments, including the Functional Independence Measure (FIM) and Brunnstrom stage, as well as spasticity evaluations using the Modified Ashworth Scale and the Global Spasticity Index, will be obtained from patient files.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hemiplegia

Interventions

no interventionOTHER

no intervention

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * Aged between 18 and 75 years, clinically diagnosed with hemiplegia * Received botulinum toxin injection for upper and/or lower extremity spasticity * Availability of recorded data for two time points, including the Functional Independence Measure (FIM), Brunnstrom stage, Modified Ashworth Scale (MAS), Global Spasticity Index (GSI) * Documentation of injected muscles and total administered botulinum toxin dosage Exclusion Criteria: * Missing essential data (e.g., absence of FIM, MAS, GSI, or GAS at either visit) * Major interventions during the follow-up period such as surgery or initiation of intrathecal baclofen pump therapy * Severe concomitant neurological disorders (e.g., progressive neurodegenerative diseases) that interfere with assessment

Outcomes

Primary Outcomes

Change in Spasticity Severity:

Evaluated using the Modified Ashworth Scale (MAS) before and after botulinum toxin treatment. A decrease in MAS scores indicates a reduction in muscle tone and improved spasticity control.

Time frame: Baseline

Secondary Outcomes

Global Spasticity Index (GSI):

Changes in the GSI values before and after treatment will be analyzed to assess overall spasticity reduction.

Time frame: Baseline

Functional Independence Measure (FIM):

Functional outcomes will be assessed using FIM scores. An increase in total FIM score indicates improved functional independence.

Time frame: Baseline

Brunnstrom Stage:

Motor recovery stages will be evaluated according to the Brunnstrom classification, with higher stages reflecting greater motor improvement.

Time frame: Baseline

Injected Muscle Groups and Dosage:

The relationship between injected muscles, total botulinum toxin dosage, and clinical response will be analyzed to identify patterns associated with greater therapeutic benefit.

Time frame: Baseline

Botulinum Toxin Applications in Hemiplegic Patients

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes